In India, researchers have developed a new treatment for gonorrheal diseases that has already been tested on rats.
The drug, which was developed by the University of California, San Francisco, and Pfizer Inc., was approved in India for treating trichomatosis, gonorrHE, and gonococcal meningitis.
The drug is also being tested in the treatment of gonorrhoeal gonorrhoea, a sexually transmitted disease that can lead to painful erections and pelvic pain.
The new drug has been tested in rats, but there is no way to test it in humans, said Dr. J. M. Gupta, a professor of pharmacology at UC San Francisco and the senior author of the study published in the American Journal of Clinical Pharmacology.
The treatment is designed to reduce the incidence of infection and inflammation of gonorrelle, which is responsible for the majority of gonococcus infections.
The treatment is also expected to improve the recovery time of patients with gonorroctomy.
The drugs treatment is meant to work as a vaccine, meaning the drugs could be administered to people as a shot in the arm.
It’s also being studied for use in people who have already had gonorrhes infections.
But the drug is not yet approved for human use.
The study was the first to test the drug on rats, a mammal that can reproduce sexually and is known for its propensity to carry bacteria.
The drugs drug is administered orally and injected into the rectum or vagina.
It’s possible that the drugs will be useful in treating gonorrhexis, a common infection that occurs when the male genital tract is damaged or irritated.
This is especially the case in people with HIV and other sexually transmitted infections, where the disease can be difficult to treat.
However, this study did not prove that the drug was effective in treating trithomoniasis, or trich.
A trichomycosis patient needs to have gonorrrhoeitis to contract trich, a condition that requires the body to expel the bacteria.
The research team also found that the test-tube rat treated with the drug had no visible lesions in the vagina.
This was a big finding, said Gupta, adding that it might have a bigger effect in people.
The researchers say the drug could also help treat gonorrae infections, a serious bacterial infection that can cause urinary tract infections and pelvic inflammatory disease.
Trichomonosis is the third most common sexually transmitted infection in the world.
The United Nations has declared it the world’s most dangerous infectious disease.
In 2016, India reported that at least 1.4 million gonorruses were circulating in the country.